Please assess the completion status of the following clinical trial:

Trial Title: Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* Infection with HCV genotype 1~* HCV RNA \> LLOQ at screening~* Participation in a prior Gilead-sponsored study~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~* Must be of generally good health, with the exception of chronic HCV infection, as determined by the Investigator~* Must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments~Key Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Co-infection with HIV or hepatitis B virus (HBV)~* Current or prior history of clinical hepatic decompensation (Groups 1 and 2 only)~* Hepatocellular carcinoma (HCC)~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF+RBV 12 weeks (Group 1) (Type: EXPERIMENTAL): Participants who failed a prior SOF+RBV ± pegylated interferon (Peg-IFN) regimen will receive LDV/SOF FDC plus RBV for 12 weeks.
- LDV/SOF 24 weeks (Group 2) (Type: EXPERIMENTAL): Participants who failed a prior LDV/SOF ± RBV regimen will receive LDV/SOF FDC for 24 weeks.
- LDV/SOF+RBV 24 weeks (Group 3) (Type: EXPERIMENTAL): Participants with advanced compensated or decompensated cirrhosis who failed a prior SOF+RBV regimen will receive LDV/SOF FDC plus RBV for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).